Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wendling

Showing results (61-70 of 496) with videos related to

Pageof 50
Sort By:
Current Opinion in Rheumatology|June 7, 2007
Antiinflammatory treatment with bisphosphonates in ankylosing spondylitisEric Toussirot, Daniel Wendling
Expert Opinion on Pharmacotherapy|February 16, 2005
Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathiesEric Toussirot, Daniel Wendling
Annals of the Rheumatic Diseases|March 17, 2016
Flare in axial spondyloarthritis. The dark side of the outcomeDaniel Wendling, Clément Prati
Joint Bone Spine|May 13, 2017
Spondyloarthritis: An expanding cast of cellular actorsDaniel Wendling, Clément Prati
Joint Bone Spine|August 5, 2008
Are inflammation and ossification on separate tracks in ankylosing spondylitis?Pascal Claudepierre, Daniel Wendling
Immunotherapy|July 9, 2020
Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritisDaniel Wendling, Philippe Goupille
Joint Bone Spine|August 2, 2011
Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonistsDaniel Wendling, Clément Prati
La Revue Du Praticien|February 1, 2012
[Pain and joint effusion. Recent arthritis. Working diagnosis]Clément Prati, Daniel Wendling
Joint Bone Spine|March 10, 2020
Are the recommendations for the use of anti-TNF drugs during axial spondyloarthritis relevant for non-radiographic forms?Philippe Goupille, Daniel Wendling
Drugs & Aging|June 25, 2005
Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment optionsEric Toussirot, Daniel Wendling
Pageof 50

Showing results (61-70 of 496) with videos related to

Sort By:
Pageof 50
Current Opinion in Rheumatology|June 7, 2007
Antiinflammatory treatment with bisphosphonates in ankylosing spondylitisEric Toussirot, Daniel Wendling
Expert Opinion on Pharmacotherapy|February 16, 2005
Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathiesEric Toussirot, Daniel Wendling
Annals of the Rheumatic Diseases|March 17, 2016
Flare in axial spondyloarthritis. The dark side of the outcomeDaniel Wendling, Clément Prati
Joint Bone Spine|May 13, 2017
Spondyloarthritis: An expanding cast of cellular actorsDaniel Wendling, Clément Prati
Joint Bone Spine|August 5, 2008
Are inflammation and ossification on separate tracks in ankylosing spondylitis?Pascal Claudepierre, Daniel Wendling
Immunotherapy|July 9, 2020
Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritisDaniel Wendling, Philippe Goupille
Joint Bone Spine|August 2, 2011
Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonistsDaniel Wendling, Clément Prati
La Revue Du Praticien|February 1, 2012
[Pain and joint effusion. Recent arthritis. Working diagnosis]Clément Prati, Daniel Wendling
Joint Bone Spine|March 10, 2020
Are the recommendations for the use of anti-TNF drugs during axial spondyloarthritis relevant for non-radiographic forms?Philippe Goupille, Daniel Wendling
Drugs & Aging|June 25, 2005
Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment optionsEric Toussirot, Daniel Wendling
Pageof 50